Trade Names:Donatuss DC- Syrup dihydrocodeine bitartrate 7.5 mg/phenylephrine hydrochloride 7.5 mg/guaifenesin 50 mg per 5 mL
Stimulates opiate receptors in CNS; also causes suppression of cough.Guaifenesin
May enhance output of respiratory tract fluid by reducing adhesiveness and surface tension, enhancing removal of vicious mucus, and making coughs more productive and less frequent.Phenylephrine
Stimulates postsynaptic alpha-receptors, resulting in vasoconstriction, which reduces congestion.
Temporary relief of nasal congestion and dry, nonproductive cough associated with upper respiratory tract infections and allergies.
Hypersensitivity to dihydrocodeine, codeine, or any component of the product; significant respiratory depression in unmonitored settings or in the absence of resuscitation equipment; acute or bronchial asthma or hypercapnia; paralytic ileus; severe hypertension; severe coronary artery disease; narrow-angle glaucoma; urinary retention; peptic ulcer; pregnancy.
PO 5 to 10 mL every 4 to 6 h as needed.Children 6 to younger than 12 yr of age
PO 2.5 to 5 mL every 4 to 6 h as needed.
Store at 59° to 86°F.
Risk of paralytic ileus may be increased.CNS depressants (eg, alcohol, centrally acting antiemetics, general anesthetics, hypnotics, muscle relaxants, phenothiazines, sedatives, tranquilizers)
May cause increased drowsiness.Beta-adrenergic blockers, MAOIs
May potentiate the pressor effect of phenylephrine.Guanethidine, mecamylamine, methyldopa, reserpine, veratrum alkaloids
Hypotensive effects of these agents may be reduced.
May cause color interference with the vanillylmandelic acid test for catechols. Guaifenesin may interfere with the interpretation of the test for urinary 5-hydroxyindoleacetic acid.
Flushing; orthostatic hypotension; palpitations.
Confusion; dizziness; drowsiness; fatigue; giddiness; hallucinations; headache; increased irritability or excitement; lassitude; light-headedness; physical/psychological dependence; sedation; vivid dreams.
Pruritus; skin reactions; sweating.
Blurred vision; miosis.
Abdominal pain; anorexia; biliary tract spasm; constipation; diarrhea; dry mouth; indigestion; nausea; vomiting.
Acute renal failure; granulomatous interstitial nephritis; urinary retention.
Hypersensitivity reactions, including anaphylactic reaction.
Category C .
Excreted in breast milk.Guaifenesin
Excreted in breast milk.
Not recommended for children younger than 6 yr of age.
Use with caution; patients 60 years of age and older are more likely to exhibit adverse reactions.
Use with caution and at a reduced dosage.
Use with caution.
Use with caution in debilitated patients and those with acute abdominal condition, adrenocortical insufficiency (eg, Addison disease), biliary tract disease (including pancreatitis), circulatory shock, CNS depression, coma, convulsive disorders, delirium tremens, diabetes, fever, head injury, hypertension, hypothyroidism or hyperthyroidism, increased intracranial pressure, increased IOP, ischemic heart disease, obesity myxedema, prostatic hypertrophy, recent GI or urinary tract surgery, toxic psychosis, ulcerative colitis, or urethral structure.
Dihydrocodeine has abuse potential; may be habit forming.
May occur, especially in patients who are volume depleted or who received concurrent therapy with drugs such as phenothiazine or other agents that compromise vasomotor tone. Orthostatic hypotension may occur in ambulatory patients.
Occurs more frequently in elderly or debilitated patients, when given in combination with other agents that depress respiration, or after large initial doses in nontolerant patients. Use with caution in patients with COPD, emphysema, kyphoscoliosis, or cor pulmonale, and in patients with substantially decreased respiratory reserve, hypercapnia, hypoxia, or respiratory depression.
Cold and clammy skin, convulsions, CV collapse, extreme somnolence progressing to stupor or coma, pinpoint pupils, respiratory depression, skeletal muscle flaccidity.
Copyright © 2009 Wolters Kluwer Health.